Interim Report for Ortivus AB (publ) for the period January – June 2025

2025-08-26 08:30

A significant impact for the patient and for the healthcare system as a whole, including its costs.

April-June 2025

Net sales increased by 11% to SEK 19.7 (17.7) million.
Gross margin increased to 51% (30%).
EBITDA amounted to SEK -4.7 (-7.7) million.
Adjusted EBITDA amounted to SEK 0.4 (-7.7) million.
Net profit after tax amounted to SEK -6.5 (-8.3) million.
Earnings per share before and after dilution amounted to SEK -0.15 (-0.19).

January-June 2025

Net sales decreased by 5% and amounted to SEK 37.8 (39.7) million.
The gross margin increased to 46 (36)%.
EBITDA amounted to SEK -6.1 (-9.1) million.
Adjusted EBITDA amounted to SEK -1.0 (-9.1) million.
Net profit after tax amounted to SEK -8.9 (-10.5) million.
Earnings per share after tax before and after dilution amounted to SEK -0.20 (-0.24).

Significant events during and after the end of the period

Ortivus’ annual International User Forum was held in Birmingham at the end of April, with attendance from all international customers. Participants received updates on iOS, cloud-based solutions, cybersecurity, and data capture.
ST Engineering in Singapore extended its agreement in April for the delivery of Ortivus MobiMed ePR for a further two years, with an order value of SEK 2.9 million.
Northern Ireland Ambulance Service extended its contract for the delivery of Ortivus MobiMed ePR for a further two years, with an order value of SEK 5.5 million.
Tervisekassa, Telia Eesti AS and Ortivus reached an agreement to terminate an ongoing project. Ortivus’ role in the project was to deliver the MobiMed ePR as a SaaS-based solution. The impact on earnings in Q2 2025 amounted to SEK -5.1 million.
South Western Ambulance Service NHS Foundation Trust extended its contract for the delivery of Ortivus MobiMed ePR for a further two years, with an order value of SEK 27.7 million.
Following the end of the quarter, South Central Ambulance NHS Foundation Trust chose to extend its contract for the delivery of Ortivus MobiMed ePR for a further two years, with an order value of SEK 16.8 million.
On 25 August, the Board of Directors convened an extraordinary general meeting, proposing a fully guaranteed rights issue of approximately SEK 54 million.

About Ortivus

Ortivus has extensive experience in mobile communication solutions and a unique understanding of clinical healthcare. We develop interactive and user-friendly solutions that support diagnostics, increase efficiency, and deliver long-term cost savings for healthcare providers. By integrating our solutions with electronic health records, dispatch systems, and national registries, we ensure fast and secure information management, a crucial factor in creating a more integrated care process.

Our solutions save valuable time for healthcare professionals, optimise resource use, and reduce the need for avoidable patient transports, resulting in more cost-effective and patient-centred care. With our combination of advanced technology and deep clinical expertise, we support our customers in meeting the healthcare challenges of today and tomorrow.

Ortivus Class A and Class B shares are listed on the NASDAQ First North Growth Market and the company’s Certified Adviser is FNCA Sweden AB.

Read more about our solutions at www.ortivus.com

Interim Report April June 2025

Get in touch

To ensure a smooth and efficient healthcare chain

Create better operational conditions through smarter information sharing between ambulance services and hospitals.

Get in touch

Interim Report for Ortivus AB (publ) for the period January – June 2025

To ensure a smooth and efficient healthcare chain

Cookie consent